Configure the table properties *Orphan drug status #chimeric antigen receptor T cell (CAR T) therapy intravenous (IV); Prescription Drug User Fee Act (PDUFA) Cell therapy: Aims to replace or repair...

Cover image for Quarterly Drug Pipeline: April 2025 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-april-2025 Prime...

Cover image for Quarterly Drug Pipeline: July 2025 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-july-2025 Prime...

Cover image for Quarterly Drug Pipeline: October 2025 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-october-2025...

cover image for Quarterly Drug Pipeline: January 2026 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-january-2026...

cover images for Quarterly Drug Pipeline: April 2026 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-april-2026 Prime...

Cover image for Quarterly Drug Pipeline: July 2026 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-july-2026 Prime...

Editor's message Editorial team Cell therapy= Transplantation of healthy cells to replace or repair damaged ones *Orphan drug status PDUFA= Prescription Drug User Fee Act IV= intravenous...

Prime's recent analysis shows that patients with obesity stopped using a GLP-1 medication within the first few years of treatment.

Among the key findings from the study — among 4,066 members, Prime/MRx found 1 in 3 stayed on their GLP-1 and 27% took their medication as intended